SML3320
KRA-533
≥98% (HPLC)
别名:
4-(4-(2-Bromoacetamido)butyl)benzoic acid, 4-[4-[(Bromoacetyl)amino]butyl]benzoic acid, KRAS Agonist-533, NSC 112533, NSC112533, p-[4-(2-Bromoacetamido)butyl]benzoic acid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H16BrNO3
化学文摘社编号:
分子量:
314.18
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI
1S/C13H16BrNO3/c14-9-12(16)15-8-2-1-3-10-4-6-11(7-5-10)13(17)18/h4-7H,1-3,8-9H2,(H,15,16)(H,17,18)
SMILES string
O=C(O)C1=CC=C(CCCCNC(CBr)=O)C=C1
InChI key
WZQJLTLURXNPQG-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
KRA-333 is a potent and selective KRAS agonist that binds directly to the GTP/GDP binding pocket of KRAS preventing the cleavage of GTP into GDP and caucusing accumulation of activated GTP-KRAS and suppression of cell growth. KRA-333 promotes apoptosis and autophagic cell death of cancer cells and inhibits growth of mutant KRAS lung cancer in xenografts mice model.
Potent and selective KRAS agonist that binds directly to the GTP/GDP binding pocket caucusing accumulation of activated GTP-KRAS and suppression of cell growth
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X
Molecular Cancer, 18 (2019)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持